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INTRODUCTION
Nowadays, it is necessary to involve the patient in 
the process of pharmacotherapy providing quality 
outpatient care as it is a patient who is the main 
participant in this process.[1-3] Hence, it is important 
to prescribe pharmacotherapy taking into account the 
patients’ individual preferences in the choice of drugs 
and economic opportunities to buy them.[4,5]
The analysis of scientific and informational materials 
showed that at present, research on the quality 
of providing outpatient care to the population is 
fragmentary and there is no systematic approach to this 
problem.[6,7] Most pharmacoeconomic methods are not 
adapted to conducting research in outpatient treatment 
since they do not take into account the economic 
characteristics and consuming capacity of patients.[8-10] 
The current situation requires the development of a 
methodological approach to the analysis of the drug 
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assortment during pharmacoeconomic research which 
involves an integrated assessment of a significant 
number of characteristics.
The purpose of our study is to develop a methodology 
for multi-aspect matrix analysis of the drug range 
prescribed in outpatient clinics.
MATERIALS AND METHODS
In the process of research, we used such methods as 
systemic and structural analysis and pharmacoeconomic 
ones. The objects of the study were 390 outpatient cards 
of patients at the age of 7–17 years with ENT diseases; 
125 expert questionnaires of otolaryngologists and 
50 questionnaires of a sociological survey of parents 
of patients with ENT diseases; official sources 
of information: “State Register of Medicines;” 
“Encyclopedia of Drugs: Register of Medicines in 
Russia;” “Vidal Reference Book. Drugs in Russia;” 
Reference book by M.D. Mashkovsky “Drugs;” 
“Handbook of drug synonyms;” and Price lists of 
implementation center “Protek” in Kursk (Russia).
ABSTRACT
Aim: The purpose of our study is to develop a methodology for multi-aspect matrix analysis of the drug range prescribed 
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RESULTS AND DISCUSSION
The analysis of existing methods of pharmacoeconomic 
studies (ABC, VEN, and XYZ analyzes) showed that 
most of them are focused on analyzing the structure of 
the drug assortment from the economic point of view. 
In this regard, we consider it relevant to conduct drugs 
examination not only in terms of their frequency of 
prescribing and treatment costs but also in terms of 
their prescribing rationality in outpatient clinics and 
the degree of compliance with consumer criteria.
To obtain a generalized evaluation of drugs, we 
proposed an original technique for a multi-aspect 
matrix analysis of the drug range. This technique is a 
tool for drug positioning by integrating a significant 
number of drug indicators in a multidimensional 
analytical matrix and also for obtaining a generalized 
assessment of a drug and recommendations for 
inclusion it in the assortment list for the treatment of a 
specific nosology in outpatient clinics.
The multi-aspect matrix analysis of the drug range 
is based on a multidimensional model formed by 
five pharmacoeconomic indicators of the drug: 
Pharmacotherapeutic efficacy, degree of compliance 
with consumer criteria, cost of drugs, costs of 
a drug treatment course, and frequency of drug 
administration.
The main advantages of the proposed method are as 
follows:
1. Facilitation and justification of the drug choice in 
the formation of assortment lists.
2. Determination of drugs with optimal values for all 
pharmacoeconomic indicators and as a consequence 
the best result of an integrated assessment.
3. Development of drug complexes with desired 
consumer criteria in various price categories.
4. The ability to determine replacement drugs along 
with the main ones.
The implementation of multi-aspect matrix analysis 
involves the sequential implementation of four 
stages: The formation of the drug assortment for 
the analysis, the construction of a multidimensional 
matrix, the interpretation of analysis results, and 
the development of brand portfolios of drugs with 
specified characteristics.
1 Stage
We suppose that the formation of the drug range is 
reasonable to carry out on the basis of expert analysis 
by including drugs from different pharmacological 
groups with high and average values of “weighted 
mean” ratings.
The group of mandatory drugs (O) with high values 
of “weighted mean” ratings and absolute compliance 
with consumer criteria can be represented as the 
“main” group of drugs. A group of important drugs (I) 
with average values of “weighted mean” ratings and 
incomplete compliance with consumer criteria should 
be considered as replacement drugs which usage is 
reasonable in the absence or inability to prescribe the 
main drugs.
2 Stage
Then, we constructed the matrix [Figure 1] where the 
results of the expert analysis are reflected horizontally. 
The integrated results of the ABC analysis of prescribing 
frequency and costs of treatment course with the 
projection of high-cost, medium-cost, and low-cost 
drugs with high and medium frequencies of prescription 
are reflected vertically. The degree of drug compliance 
with consumer criteria is reflected diagonally.
3 Stage
Next, we formed seven cells with the corresponding 
conditional names and certain consumer criteria:
1. The drug efficacy (mandatory and important);
2. The drug cost for a course of treatment (high, 
medium, and low cost);
3. The drug price (high, medium, and low cost);
4. The novelty degree of the recommended drugs 
(modern, relatively new, and traditional);
5. The drug production (original/replicated);
6. The possibility of using drugs in outpatient clinics;
7. The usability of the dosage form at home.
Then, in each price category (“Golden,” “Silver,” 
and “Bronze”), we determined leading drugs with the 
highest “weighted mean” ratings and the maximum 
compliance with consumer criteria (“Leaders”). The 
remaining drugs with low “weighted mean” ratings 
and incomplete compliance with consumer criteria fall 
into the category of replacement (“Followers”).
4 Stage
Next, we carried out the grouping of drugs from 
the required groups indicating the main drugs, 
replacement drugs, and calculating the cost of brand 
portfolios in three price segments (Golden, Silver, and 
Bronze). As a rule, the groups “Golden Leader” and 
“Golden Follower” are presented by drugs with high 
pharmacotherapeutic efficacy. Furthermore, they are 
original, expensive, and meet consumer characteristics 
as much as possible.
In the “Silver Leader” and “Silver Follower” groups, 
there are drugs with high pharmacotherapeutic 
efficacy, original and replicated medications, medium 
cost, with medium or low cost, and meeting consumer 
criteria partially or completely.
The groups “Bronze Leader” and “Bronze Follower” 
are represented by drugs with high pharmacotherapeutic 
Irina V. Spichak, et al.
2393Drug Invention Today | Vol 11 • Issue 10 • 2019
effectiveness, generics, with low cost, and with a low 
degree of compliance with consumer criteria.
Thus, according to the results of a multi-aspect matrix 
analysis, the formed brand portfolios of drugs have 
high pharmacotherapeutic efficacy taking into account 
various costs and consumer characteristics: Duration 
of treatment, the usability of the dosage form at home, 
degree of the drug novelty, etc.
We conducted testing of multi-aspect matrix analysis 
on the example of chronic tonsillitis in children 
as one of the most common forms of diseases in 
pediatrics.
In accordance with the methodical approach to 
conducting a multi-aspect matrix analysis which is 
based on the results of ABC and expert analyzes in 
view of consumer preferences, we carried out the 
Degree of compliance with consumer criteria Results of expert analysis
Mandatory drugs (Group 
«О») Leaders
Important drugs (Group «I») 
Followers
Results of integrated 
ABC and frequency 
analyses
The group of high-cost 
drugs with high and 
medium frequency of 
prescription
Gold
High and medium frequency of 
prescription
High cost
Mainly modern
Mainly original
Positively proven in pediatric 
use
Mainly convenient dosage form
High-cost drugs
High and medium frequency of 
prescription
High cost
Mainly modern
Mainly replicated
Having restrictions in pediatric use
Relatively convenient dosage form
High-/medium-cost drugs
The group of medium-
cost drugs with high and 
medium frequency of 
prescription
Silver
High and medium frequency of 
prescription
Medium cost
Mainly new
Mainly original
Positively proven in pediatric 
use
Mainly convenient dosage form
Medium-cost drugs 
High and medium frequency of 
prescription
Medium cost
Mainly new
Mainly replicated
Having restrictions in pediatric use
Relatively convenient dosage form
Medium-/low-cost drugs
The group of low-cost 
drugs with high and 
medium frequency of 
prescription
Bronze
High and medium frequency of 
prescription
Low cost
Mainly traditional
Original/replicated
Positively proven in pediatric 
use
Mainly convenient dosage form
Low-cost drugs
High and medium frequency of 
prescription
Low cost
Mainly traditional
Original/replicated
Having restrictions in pediatric use
Relatively convenient dosage form
Low-cost drugs
Figure 1: The matrix of a multi-aspect matrix method for analyzing the drug range and the interpretation of its results
Figure 2: The multidimensional matrix of a multi-aspect analysis of the drug assortment list for the treatment of compensated 
chronic tonsillitis in children in outpatient clinics
Degree of compliance with consumer criteria Results of expert analysis
Basic drugs
Group “O”
Leaders
Replacement drugs
Group “I”
Followers
Results of integrated ABC- 
and frequency 
analyses
The group of high-cost drugs with high and 
medium frequency of prescription
Gold
Tonsilgon N (drops),
Multi-tabs,
Immuno Plus
Bioparox,
Tonsilotren,
Lysobact,
Centrum
The group of medium-cost drugs with high 
and medium frequency of prescription
Silver
Tonsilgon N (pills),
Multi-tabs Junior*
Hexaspray,
Hexalyse,
Picovit Plus, 
Alphavit for kids, 
Complivit
The group of low-cost drugs with high and 
medium frequency of prescription
Bronze
Faringosept,
Jungle
Inhalypt,
Strepsils,
Revit,
Ascorutin
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formation of brand portfolios for the treatment of 
chronic tonsillitis in children.
Initially, we did the formation of the drug assortment 
list for chronic tonsillitis with various forms of 
severity according to the groups of drugs obtained 
during expert analysis. Thus, the main drug list for the 
treatment of compensated chronic tonsillitis is formed 
by 13 mandatory drugs (“O”) with high “weighted 
mean” ratings (from 1.5 to 1.7); important drugs (“I”) 
in the amount of four items with low “weighted mean” 
ratings (from 1.2 to 1.4).
Then, we constructed a multidimensional matrix 
filled and introduced by drugs in accordance with 
the results of expert analysis, the integrated results 
of the ABC analysis concerning the frequency of 
prescription and costs of treatment and the degree 
of the drug compliance with consumer criteria 
[Figure 2].
At the next stage in accordance with the ATC 
classification, we identified leaders in each price group 
of drugs that received the highest “weighted mean” 
ratings with the maximum compliance with consumer 
criteria. These drugs are subsequently presented as the 
main drugs. The rest drugs with low values of “weighted 
mean” ratings and incomplete compliance with consumer 
criteria are included in the substitution category.
At the final stage, we classified drugs from the 
necessary pharmacological groups, indicating the 
main drugs, replacement drugs, and calculating 
the cost of brand portfolios in three price segments 
(“Golden,” “Silver,” and “Bronze”) to treat various 
forms of chronic tonsillitis.
In particular, the group “Golden Leader” for the 
treatment of compensated chronic tonsillitis is formed 
by two drugs (drops Tonsilgon N and tab. Multi-tabs 
Immuno Plus) with high “weighted mean” ratings, 
high pharmacotherapeutic efficacy, expensive, with 
maximum compliance with consumer characteristics 
and recommended for mandatory inclusion in the 
brand portfolio as main drugs.
CONCLUSION
Thus, we made progress in the formation of three brand 
portfolios of drugs for the treatment of compensated 
chronic tonsillitis of various price categories 
(more than 500 rubles, from 200 to 500 rubles, and 
<200 rubles). Hence, pharmacotherapeutic complex 
No 1 for the treatment of chronic compensated 
tonsillitis with an average price of the treatment course 
is about 700 rubles and is formed by such modern 
drugs as Tonsilgon N (drops), Bioparox, Tonsilotren, 
Lysobact, Multi-tabs Immuno Plus, and Centrum. The 
indicated complex of drugs has a high therapeutic 
efficacy and drugs are presented in convenient dosage 
forms for children: Drops, tablets, and aerosol that 
are possible to use by young children. The main side 
effect is allergy.
Hence, we made a multi-aspect matrix analysis. 
The result is the formation of drug brand portfolios 
for the treatment of compensated chronic tonsillitis. 
These brand portfolios are optimal from the viewpoint 
of pharmacotherapeutic, economic, and consumer 
criteria. The drug brand portfolios give an opportunity 
to doctors and patients to choose a complex of drugs 
that meet best the requirements of pharmacotherapeutic 
efficacy, as well as the expectations and purchasing 
power of patients.
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